
Rostraver mom defies odds with lifelong Herceptin, becomes cancer 'super responder'
Thirteen years after a metastatic HER2-positive breast cancer diagnosis, Kate Crawford of Rostraver defied an 18–24 month prognosis thanks to lifelong Herceptin infusions; doctors now see no evidence of cancer, earning her the label of a 'super responder' and prompting research into whether such responses can cure metastatic cancer, while she continues treatment and advocates for patients.